Kreuter J
Institut für Pharmazeutische Technologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany.
Infection. 1991;19 Suppl 4:S224-8. doi: 10.1007/BF01644038.
Colloidal drug carriers such as liposomes and nanoparticles are easily taken up by phagocytic cells and accumulate in the organs of the reticuloendothelial system. Therefore, they hold promise as carriers for the treatment of intracellular infections with antibiotics that would normally not find easy access to intracellular sites. Consequently, in in vitro and in vivo experiments the therapeutic efficacy of substances such as amphotericin B, dihydrostreptomycin, amikacin, ampicillin, stibogluconate against a number of microorganisms including Leishmania donovani, Candida albicans, Staphylococcus aureus, Mycobacterium avium, Listeria monocytogenes, and Salmonella typhimurium was increased significantly by binding to liposomes and nanoparticles.
脂质体和纳米颗粒等胶体药物载体很容易被吞噬细胞摄取,并在网状内皮系统的器官中蓄积。因此,它们有望作为载体,用于治疗通常难以进入细胞内位点的抗生素所致的细胞内感染。所以,在体外和体内实验中,两性霉素B、二氢链霉素、阿米卡星、氨苄西林、葡糖酸锑钠等物质与脂质体和纳米颗粒结合后,对包括杜氏利什曼原虫、白色念珠菌、金黄色葡萄球菌、鸟分枝杆菌、单核细胞增生李斯特菌和鼠伤寒沙门氏菌在内的多种微生物的治疗效果显著提高。